The Poly(lactic-co-glycolic acid) (PLGA) Market is projected to grow from USD 125 million in 2024 to USD 321 million by 2030, at an impressive CAGR of 16.6%, according to a new industry report. This rapid growth is being fueled by increased adoption of PLGA across sectors such as healthcare, biotechnology, medical research, packaging, textiles, and agriculture.
PLGA’s popularity stems from its biocompatibility and biodegradability, making it an ideal material for drug delivery systems, 3D-printed scaffolds, implants, and biomedical devices.
Key players driving this innovation include:
- Evonik (Germany) – Partnered with BellaSeno for 3D-printed scaffolds in bone regeneration.
- Ashland (US) – Expanded Viatel biopolymer R&D facility in Ireland.
- Corbion NV, Mitsui Chemicals, Merck, and Jinan Digang Bioengineering Co. Ltd.
North America holds the largest market share, thanks to its strong pharmaceutical base, investment in biomedical R&D, and supportive regulations favoring sustainable materials.
Emerging applications such as tissue engineering scaffolds, biodegradable sutures, and sustained drug delivery systems are also boosting demand, making PLGA a critical component in the shift toward eco-conscious medical solutions.